Reply to “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy”

Coto‐Hernández, Rubén; Ruano, María Teresa Fábregas

doi:10.1111/jth.14852

Cited by 5 publications

(1 citation statement)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bleeding disorders reported in COVID-19 patients are surprisingly rare -approximately 2% of cases -and present mostly with mild petechiae due to depletion of platelet [82]. However, the common coagulopathy in severe COVID-19 seems to be local pulmonary thrombosis, a vast portion of ICU patients develop a systemic disseminated intravascular coagulation (71.4% of non-survivors vs. 0.6% of survivors), though it may still be a systemic picture of massive local endothelial injury during ARDS development [62,83,84]. Nevertheless, the first reports are available, which document the beneficial effect of heparin use on the outcome from COVID-19 [83].…”

Section: Coagulation and Thrombosis In Covid-19mentioning

confidence: 99%

COVID-19 — Toward a comprehensive understanding of the disease

et al. 2020

View full text Add to dashboard Cite

The evidence on the pathophysiology of the novel coronavirus SARS-CoV-2 infection is rapidly growing. Elucidating why some patients suffering from COVID-19 are getting so sick, while others are not, has become an informal imperative for researchers and clinicians around the globe. The answer to this question would allow rationalizing the fear surrounding this pandemic. Understanding of the pathophysiology of COVID-19 relies on unraveling of interplaying mechanisms, including SARS-CoV-2 virulence, human immune response, and complex inflammatory reactions with coagulation playing a major role. An interplay with bacterial co-infections, as well as the vascular system and microcirculation affected throughout the body should also be examined. More importantly, a comprehensive understanding of pathological mechanisms of COVID-19 will increase the efficacy of therapy and decrease mortality. Herewith, the authors present a combined viewpoint based on the current state of knowledge on COVID-19: beginning from the virus, its transmission, and mechanisms of entry into the human body, through the pathological effects on the cellular level, up to immunological reaction, systemic and organ presentation. Last but not least, currently available and possible future therapeutic and diagnostic options are briefly commented on. (Cardiol J 2020; 27, 2: 99-114)

show abstract

Section: Coagulation and Thrombosis In Covid-19mentioning

confidence: 99%

COVID-19 — Toward a comprehensive understanding of the disease

et al. 2020

View full text Add to dashboard Cite

show abstract

Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2–Positive Patients Recovering from COVID-19: a Case Report and Review of Literature

Yeganegi

Fattahi

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Current Perspectives of Anticoagulation in Patients With COVID-19

Gavioli¹,

Sikorska²,

Man³

et al. 2020

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.

show abstract

Reply to “Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy”

Abstract: Ultrasoundguided minimally invasive autopsy as a tool for rapid post-mortem diagnosis in the 2018 Sao Paulo yellow fever epidemic: correlation with conventional autopsy.

Cited by 5 publications

References 4 publications

COVID-19 — Toward a comprehensive understanding of the disease

COVID-19 — Toward a comprehensive understanding of the disease

Management and Prevention of Cerebrovascular Accidents in SARS-CoV-2–Positive Patients Recovering from COVID-19: a Case Report and Review of Literature

Current Perspectives of Anticoagulation in Patients With COVID-19

Contact Info

Product

Resources

About